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Tuberous sclerosis complex is required for tumor
maintenance in MYC-driven Burkitt’s lymphoma
Götz Hartleben1,2, Christine Müller1,2, Andreas Krämer2, Heiko Schimmel3, Laura M Zidek2,
Carsten Dornblut2, René Winkler4, Sabrina Eichwald2, Gertrud Kortman1, Christian Kosan4 ,
Joost Kluiver5, Iver Petersen3, Anke van den Berg5, Zhao-Qi Wang2 & Cornelis F Calkhoven1,2,*
Abstract
The tuberous sclerosis complex (TSC) 1/2 is a negative regulator of
the nutrient-sensing kinase mechanistic target of rapamycin
complex (mTORC1), and its function is generally associated with
tumor suppression. Nevertheless, biallelic loss of function of TSC1 or
TSC2 is rarely found in malignant tumors. Here, we show that TSC1/
2 is highly expressed in Burkitt’s lymphoma cell lines and patient
samples of human Burkitt’s lymphoma, a prototypical MYC-driven
cancer. Mechanistically, we show that MYC induces TSC1 expression
by transcriptional activation of the TSC1 promoter and repression of
miR-15a. TSC1 knockdown results in elevated mTORC1-dependent
mitochondrial respiration enhanced ROS production and apoptosis.
Moreover, TSC1 deficiency attenuates tumor growth in a xenograft
mouse model. Our study reveals a novel role for TSC1 in securing
homeostasis between MYC and mTORC1 that is required for cell
survival and tumor maintenance in Burkitt’s lymphoma. The study
identifies TSC1/2 inhibition and/or mTORC1 hyperactivation as a
novel therapeutic strategy for MYC-driven cancers.
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Introduction
TSC1/2 is a critical upstream regulator of the mechanistic target of
rapamycin complex (mTORC) 1 kinase. TSC1 (hamartin) stabilizes
TSC2 (tuberin), which is the GTPase-activating protein (GAP) for
Rheb (Ras homolog enriched in brain) in the regulation of mTORC1
(Mieulet & Lamb, 2010). Germline mutations in either TSC1 or TSC2
result in the development of benign tumors (hamartomas) due to
hyperactive mTORC1 signaling, which, however, usually does not
result in malignancy. Moreover, loss of function of either TSC1 or
TSC2 is rarely found in malignant tumors (Mieulet & Lamb, 2010)
with some known exceptions like somatic mutations of TSC1 in
bladder cancer (Pymar et al, 2008) or TSC2 in hepatocellular carci-
noma’s (Huynh et al, 2015). Therefore, retaining functional TSC1/2-
mTORC1 regulation may be beneficial for certain cancer cells
(Mieulet & Lamb, 2010). An important role of TSC1/2 in metabolic
homeostasis was revealed in hematopoietic stem cells (HSCs) where
deletion of TSC1 results in elevated mTORC1 activity and increased
ROS production with detrimental effects on HCS function and
survival (Chen et al, 2008). A database survey revealed that TSC1-
mRNA expression is the highest in Burkitt’s lymphoma-derived cell
lines compared to 36 different tumor-type cell lines in the Cancer
Cell Line Encyclopedia (CCLE; http://www.broadinstitute.org/ccle)
(Fig EV1A). Moreover, the COSMIC database (http://cancer.sanger.
ac.uk/cancergenome/projects/cosmic/) lists no mutations for TSC1
or TSC2 in Burkitt’s lymphoma and they are not under the
recurrently mutated genes in Burkitt’s lymphoma identified by
genomic approaches in two studies (Richter et al, 2012; Schmitz
et al, 2012). Burkitt’s lymphoma is an aggressively growing malig-
nancy characterized by a MYC translocation that induces very high
expression levels of the proto-oncogenic transcription factor MYC
(Molyneux et al, 2012). MYC promotes cell proliferation by multiple
mechanisms including stimulation of cell cycle progression, ribo-
some biogenesis, tRNA synthesis, translation and metabolic adjust-
ments to increase provision of metabolic intermediates (Dang,
2012).
In this study, we reveal that MYC stimulates the expression of
the mTORC1-inhibitor TSC1 by a feed-forward mechanism combin-
ing TSC1 transcriptional activation and alleviation of microRNA
miR-15a-mediated repression. Loss of TSC1 function in Burkitt’s
lymphoma cells results in enhanced mitochondrial respiration and
accumulation of toxic ROS levels. Our study is the first to provide
evidence that TSC1 has tumor maintenance function designating the
TSC1/2-mTORC1 axis as a novel therapeutic target in MYC-driven
Burkitt’s lymphoma.
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Results
MYC controls mTORC1 through upregulation of TSC1/2 in
Burkitt’s lymphoma
To examine a potential MYC-TSC1 regulation in Burkitt’s lymphoma
(BL), we analyzed TSC1/2 expression in human BL cell lines, which
express high levels of MYC, in comparison with low MYC expressing
Hodgkin lymphoma (HL) cell lines. Immunoblotting revealed that
high expression of TSC1/2 correlates with high MYC expression in BL
cells and that low TSC1/2 expression correlates with low MYC in HL
cells (Fig 1A). To investigate MYC-TSC1/2-mTORC1 regulation, we
used the EBV immortalized human B-cell line P493-6 that carries a
conditional, tetracycline-repressibleMYC allele to study MYC-induced
B-cell proliferation (Pajic et al, 2000). Also in this system, high MYC




Figure 1. MYC controls mTORC1 signaling through regulation of the TSC1.
A Immunoblot of expression levels of MYC, TSC1, TSC2, and b-actin loading control in high MYC Burkitt’s lymphoma (BL) cells compared to low MYC Hodgkin
lymphoma (HL) cells.
B Immunoblots showing expression levels of MYC, TSC1, TSC2, or b-actin loading control in P493-6 cells treated with tetracycline for 72 hours (+Tet) or in untreated
cells (Tet).
C Relative TSC1 and TSC2 mRNA expression levels determined by qRT–PCR for high MYC (Tet) versus low MYC (+Tet) P493-6 cells treated for 24 h with tetracycline
(mean  SD, n = 3 technical replicates). *P < 0.05; **P < 0.01; statistical relevance was determined by unpaired t-test (two-tailed).
D qRT–PCR analysis of TSC1 mRNA levels upon MYC suppression for 24 h–72 h (+Tet). Immunoblots for 24 h and 48 h (+Tet) show S6K and phosphorylation (P-) of S6K
as downstream mTORC1 target, and b-actin loading control. For 72 h (+Tet), the immunoblots show expression of MYC and phosphorylation (P-) of downstream
mTORC1 targets S6K and S6, and a-tubulin as loading control.
E Upper immunoblot shows the reduction in TSC1 levels upon expression of two different TSC1-specific shRNAs compared to scrambled control shRNA in P493-6 cells.
Other blots show the expression levels of TSC2, S6K/P-S6K, S6/P-S6, and a-tubulin for loading control.
F Immunoblots of indicated proteins in P493-6 cells with high MYC (Tet, 72 h) or low MYC (+Tet, 72 h) levels either treated with rapamycin or solvent.
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(+Tet, 72 h) resulted in a reduction of TSC1 and TSC2 (Fig 1B). Quan-
titative real-time PCR (qRT–PCR) analysis revealed a strong reduction
of TSC1 mRNA versus a minor reduction of TSC2 mRNA following
24-h repression of MYC (+Tet; Fig 1C). In addition, the decline in
TSC1 protein occurred prior to the TSC2 reduction at the earlier 24-h
time point (Fig EV1B). Since TSC1 stabilizes TSC2, these data suggest
that low MYC levels primarily affect TSC1 expression followed by
destabilization of TSC2. TSC1/2 is the major inhibitor of mTORC1
signaling and accordingly expression of high levels of MYC (Tet) in
P493-6 cells resulted in a strong reduction of phosphorylation of the
mTORC1 substrate p70-S6-kinase1 (S6K) and its substrate ribosomal
protein S6 measured over 24–72 h (Fig 1D). Knockdown of TSC1 in
MYC expressing P493-6 (Tet) resulted in lower levels of TSC2 and
in stimulation of mTORC1 signaling, revealing integral MYC-TSC1/
TSC2-mTORC1 regulation (Fig 1E). The phosphorylation of S6K and
S6 in the low MYC (+Tet) cells is abrogated by rapamycin showing
that the observed effects are mTORC1 linked (Fig 1F).
Next, we analyzed the expression of MYC and TSC1 by immuno-
histochemistry of human BL tissue samples versus control reactive
lymph node tissue samples. We found significantly higher expres-
sion of MYC and TSC1 protein levels in the BL samples compared to
the B lymphocytes that reside in the germinal centers of control
lymph nodes (Figs 2A and EV2A and E). In addition, in a second
cohort of BL patient samples, we found significantly higher expres-
sion of TSC1 and TSC2 proteins by immunoblotting in BL compared
to control tonsils and reactive lymph nodes (LN) (Figs 2B and
EV2B). Thus, our results show that high TSC1/2 expression
correlates with high MYC expression in BL and BL cell lines. Finally,
S6K-phosphorylation levels as determined by immunoblotting were
lower for BL patient samples compared to reactive lymph node
controls (Fig EV2C). S6-phosphorylation was virtually absent in
seven BL tissue samples and present in one BL sample. In the reac-
tive control lymph nodes, S6-phosphorylation staining was observed
in a mosaic fashion and with different intensities (Fig EV2D and F).
Altogether, our data show that TSC1/2 expression is remarkably
high in MYC BL systems and suggesting that during oncogenesis
MYC maintains control of mTORC1 signaling through stimulation of
TSC function.
Loss of TSC1 function is lethal for MYC-driven cancer cells
Given the anticipated role of TSC1 as a tumor suppressor, these
rather unexpected findings led us to examine whether TSC1 upregu-
lation is required for the oncogenic potential of MYC in the cellular
BL model. Strikingly, TSC1 knockdown in high (Tet) MYC P493-6
cells resulted in a strong decrease in viable cell numbers (Fig 3A,
left graph). AnnexinV/7AAD staining revealed that apoptosis was
increased in TSC1 knockdown cells (Fig 3A, right graph), suggesting
that the upregulation of TSC1 by MYC is required for cell survival.
Notably, the decreased P493-6 cell viability in response to TSC1
knockdown could be rescued by treatment with the mTORC1 inhi-
bitor rapamycin, showing that enhanced mTORC1 activity is respon-
sible for the increased apoptosis (Fig 3B). To further analyze a
potential synthetic lethal interaction between MYC deregulation and
A B
Figure 2. Levels of TSC1 and MYC correlate in Burkitt’s lymphoma.
A Elevated TSC1 and MYC expression in BL (cohort 1). Example of immune staining of TSC1, MYC, the B-cell marker CD20, and DAPI nuclear DNA-staining in germinal
centers of control lymph nodes (upper rows) and samples from BL patients (lower rows). Boxplots at the right show quantification of TSC1 or MYC staining from
control germinal centers and BL samples (see materials and methods; the horizontal line shows the median, whiskers show maximum and minimum data points, and
the box represents the first to the third quartiles, n = 56 fields for tumor samples and n = 21 fields for control germinal centers; scale bar = 100 lm).
B Quantification of immunoblot analysis of TSC expression in BL (cohort 2) (n = 13) compared to healthy tonsils (n = 3) or reactive lymph nodes (n = 3) (mean  SD)
shown in Fig EV2B.
Data information: In all graphs *P < 0.05; **P < 0.01; ***P < 0.001, statistical relevance was determined by unpaired t-test (two-tailed).
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mTORC1 hyperactivation, we made use of an U2OS cell line
expressing a MYC-ER fusion protein (Liu et al, 2012). In cells with
physiological MYC activity (OHT), the activation of mTORC1
through knockdown of TSC1 had little effect on cell viability.
However, the combined activation of MYC (+OHT) and mTORC1
(TSC1 knockdown) synergistically increased apoptosis, which could
be prevented with rapamycin treatment (Figs 3C and EV3A). This
shows that cells with deregulated MYC require restriction of
mTORC1 signaling for survival and that TSC inhibition is synthetic
lethal with MYC overexpression.
In order to have a better representation of the human disease, we
studied the effect of TSC1 knockdown on viability for BL cell lines.
TSC1 knockdown reduced cell viability of all eight tested BL cell
lines (Fig 3D; see Figs EV3B–E and EV4D–E for TSC1 knockdown).
TSC1 knockdown does not reduce cell viability in the low MYC and
low TSC1 Hodgkin lymphoma (HL) cell lines KMH2 and L540
(Fig EV3F). The data suggest that high expression of TSC1 is a
specific requirement for BL cells to maintain cell survival. To inves-
tigate whether loss of TSC2 as the other part of the TSC1/2 complex
similarly affects cell survival, we knocked down TSC2 in three
selected BL cell lines. In all three cell lines, TSC2 knockdown
resulted in increased S6K-phosphorylation and reduced of cell
viability (Fig EV3G). Our findings may seem to be at odds with
studies showing that mTORC1 signaling is required for survival of
lymphomas in the El-Myc mouse model (Wall et al, 2013) or in
TCF3-activated tonic BCR signaling that activates mTORC1 (Schmitz
et al, 2012). Therefore, we hypothesized that maintaining control of
mTORC1 to prevent hypo- as well as hyperactivity is important for
Burkitt’s lymphoma survival. To test this hypothesis, we performed
a rapamycin titration experiment using the BL cell lines BL2, DG75,
and Raji. As expected, strong inhibition of mTORC1 with a high
dose of rapamycin (10 nM) severely reduced the cell viability in
both control and TSC1 knockdown cells. In contrast, the decreased
viability of the TSC1 knockdown cells was recovered by treatment
with low dose of rapamycin (30 pM), which titrated the mTORC1
activity to comparable levels of that in control cells (Figs 3E and
EV3H). Thus, a controlled level of mTORC1 activity that is in equi-
librium with MYC expression levels is critical for the survival of BL
cells and probably other MYC-driven cancer cells.
To determine whether TSC1 function is crucial for BL tumor
growth in vivo, we established xenotransplant models of the aggres-
sive human Ramos BL cell line in NOD/SCID mice. Ramos cells
stably expressing either a control shRNA or a TSC1-specific shRNA
were injected subcutaneously into NOD/SCID mice and tumor
growth was monitored. 35 days after cell injection, tumors derived
from TSC1 knockdown cells showed a reduced tumor volume to
43% compared to tumors derived from the control shRNA express-
ing cells (Fig 3F). These data indicate that knockdown of TSC1
significantly slows BL tumor growth in vivo.
Loss of TSC1 results in toxic ROS production
Next, we addressed what causes the reduced cell viability by TSC1
knockdown. Hyperactivation of mTORC1 in certain cell types results
in suppression of AKT kinase activity through negative feedback,
which is reflected by the hypophosphorylation of Thr308 and Ser493
(Harrington et al, 2004; Manning, 2004; Rozengurt et al, 2014). Since
AKT has a known anti-apoptotic activity (Ahmed et al, 1997; Dudek
et al, 1997; Kauffmann-Zeh et al, 1997; Kennedy et al, 1997), a poten-
tial inhibition of AKT could be involved in the observed cell death.
However, in a panel of BL cell lines, TSC1 knockdown either resulted
in an increase in Ser493 phosphorylation or did not change Ser493
phosphorylation of AKT, while we were unable to detect any Thr308
phosphorylation in our assay (Fig EV4A). These data suggest that
decreased AKT activity is not a cause for cell death following TSC1
knockdown. The enhanced Ser493 phosphorylation of AKT might
reflect a compensatory response to counteract apoptosis.
Excessive mitochondrial respiration might result in toxic levels
of reactive oxygen species (ROS) and apoptosis in cancer cells
(DeNicola et al, 2011). Since both mTORC1 and MYC are known to
increase mitochondrial respiration (Li et al, 2005; Cunningham
et al, 2007), we examined mitochondrial respiration and ROS
▸Figure 3. TSC1 is crucial for survival of Burkitt’s lymphoma (BL) cells.A Left graph shows the multiplication rate of P493-6 (Tet) cells expressing either a scrambled control shRNA or a TSC1-specific shRNA determined by viable cell
counting 3 days after seeding of equal number of viable cells (determined by Trypan blue exclusion; mean  SD, n = 3 biological replicates). Right graph shows
percentage of apoptotic P493-6 (Tet) cells expressing scrambled control shRNA or a TSC1-specific shRNA determined by FACS analysis of AnnexinV/7AAD-stained
cells (mean  SD, n = 3 biological replicates).
B Rapamycin treatment recovers survival of TSC1 knockdown in P493-6 cells. Relative viable cell number counts of P493-6 (Tet) cells expressing scrambled control
shRNA or TSC1-specific shRNA 14 days after seeding equal number of viable cells (Trypan blue exclusion), in the presence of 30 pM rapamycin where indicated
(mean  SD, n = 3 biological replicates).
C TSC1 knockdown is synthetic lethal with MYC deregulation. U2OS-MYC-ER cells expressing either scrambled control shRNA or TSC1-specific shRNA were treated with
hydroxytamoxifen (4-OHT) to induce MYC and rapamycin (100 nM) where indicated. Percentage of apoptotic cells was determined with Annexin/7AAD staining
4 days after MYC induction (mean  SD, n = 3 biological replicates).
D Survival rate of different BL cell lines upon TSC1 knockdown. Graphs show numbers of viable cells expressing either a scrambled control shRNA or a TSC1-specific
shRNA 3 days after seeding of equal number of viable cells (determined by Trypan blue exclusion; mean  SD, n = 3 biological replicates).
E Immunoblots of control- or TSC1-shRNA expressing BL2 or DG75 cells treated with different concentrations of rapamycin to either completely inhibit mTORC1 activity
(10 nM) or titrate the activity to control levels (30 pM), and survival rate of these cells over 7 days (mean  SD, n = 3 biological replicates); (BL2 cells were selected
for stable knockdown with puromycin, DG75 cells without selection).
F Ramos cells expressing either a TSC1-specific or a control shRNA were inoculated into NOD/SCID mice, and tumor volume was measured regularly. The immunoblot
shows the level of knockdown of TSC1 (sh-TSC1b) compared to control (sh-contr), and levels of TSC2 and phosphorylated mTORC1 target proteins before inoculation.
Tumor growth curves show mean  SEM (n = 8/group). Pictures of xenotransplanted human Ramos lymphoma tumors 35 days after inoculation. The top panels
show tumors derived from Ramos cells stably expressing control shRNA (sh-contr); the lower panels show tumors derived from Ramos cells stably expressing TSC1-
specific shRNA (sh-TSC1b).
Data information: In all graphs *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001, statistical relevance was determined by unpaired t-test (two-tailed).
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Figure 4. TSC1 function restricts oxidative phosphorylation and ROS production.
A, B TSC1 knockdown increases respiration in an mTORC1- and MYC-dependent manner. Rate of basal oxygen consumption in P493-6 (Tet) cells expressing scrambled
control shRNA or TSC-specific shRNA, treated with 20 nM rapamycin for 12 h, or tetracycline to repress MYC for 48 h where indicated (A) or in response to 10 lM
of the chemical uncoupler DNP to determine maximal respiration or 10 lM of the ATP synthase inhibitor oligomycin where indicated (B) (mean  SD, n = 6
biological replicates).
C, D Ratio of mitochondrial to genomic DNA (C) and expression of cytochrome C (CYCS) or ATP5G1 mRNAs (D) determined by qRT–PCR in P493-6 (Tet) cells expressing
either scrambled control shRNA or a TSC1-specific shRNA, and treated with 20 nM rapamycin for 12 h where indicated (mean  SD, n = 3 technical replicates).
E TSC1 knockdown results in elevated ROS levels in a MYC- and mTORC1-dependent manner. FACS analysis of DCF-DA-stained P493-6 (Tet) cells expressing
scrambled control shRNA or a TSC1-specific shRNA to evaluate ROS production and treated with 20 nM rapamycin for 12 h and tetracycline for 48 h where
indicated (mean  SD, n = 3 biological replicates).
F TSC1 knockdown results in increased phosphorylation of SAPK/JNK. Immunoblot of SAPK/JNK Thr183/Tyr185-phosphorylation in P493-6 (Tet) cells expressing
scrambled control shRNA or a TSC1-specific shRNA. a-tubulin expression serves as loading control.
G Antioxidant treatment rescues cells from death caused by TSC1 knockdown. Relative viable cell number counts of P493-6 (Tet) cells expressing scrambled control
shRNA or TSC1-specific shRNA 3 days after seeding equal number of viable cells (Trypan blue exclusion), in the presence of 10 lM of the antioxidant BHA where
indicated (mean  SD, n = 3 biological replicates).
Data information: In all graphs *P < 0.05; **P < 0.01; ***P < 0.001, statistical relevance was determined by unpaired t-test (two-tailed).
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production in the cellular BL model. TSC1 knockdown in P493-6
cells increased total oxygen consumption as well as the ratio of
oxygen consumption over lactate production (as determined by
acidification), which was measured with the Seahorse XF extracellu-
lar flux analyzer (Fig 4A, left graph and Fig EV4B). Treatment with
rapamycin reverted these effects demonstrating the involvement of
mTORC1 signaling. Suppression of MYC by tetracycline lowered
oxygen consumption of both TSC1 knockdown and control cells
revealing MYC’s contribution in boosting mitochondrial function
(Fig 4A, right graph). In the TSC1 knockdown cells, we detected a
higher maximal respiratory capacity compared to control cells,
which was determined by treatment of the cells with the decoupling
drug 2,4-dinitrophenol (DNP; Fig 4B). In response to the ATPase
proton channel inhibitor oligomycin, oxygen consumption was
reduced to a similar extent in both the TSC1-shRNA and control
shRNA expressing cells, demonstrating that the observed alterations
in respiration are not due to proton leakage (Fig 4B). These data
show that loss of TSC1 function and the resulting increased
mTORC1 activity shifts metabolism to more mitochondrial respira-
tion. In agreement with enhanced mitochondrial oxidative function,
we found an increased ratio of mitochondrial to genomic DNA upon
TSC1 knockdown (Fig 4C), indicating enhanced mitochondrial
biogenesis. Moreover, mRNA expression of cytochrome C (CYCS)
and the subunit ATP5G1 of the mitochondrial ATPase that are
involved in oxidative phosphorylation were enhanced in TSC1
knockdown cells (Fig 4D). These alterations were reversed by rapa-
mycin treatment showing their dependence on mTORC1 function.
To expand our study from the P493-6 model to other BL cell lines,
we performed shRNA-mediated knockdown of TSC1 in Raji
(Fig EV4C and D) and DG75 (Fig EV4E) cells. This resulted in
phenotypes similar to those observed in P493-6 cells including
enhanced S6K-phosphorylation, increased oxygen consumption, and
higher expression of CYCS and ATP5G1.
To examine whether the increased mitochondrial respiration in
response to mTORC1 activation in TSC1 knockdown cells is accom-
panied by increased intracellular ROS levels, we analyzed DCF-DA-
stained cells by flow cytometry. Knockdown of TSC1 resulted in an
increase in oxidized and fluorescent DCF-DA compared to the
control cells, indicating an increase in ROS production (Fig 4E).
In agreement with enhanced oxidative stress, the ROS-sensitive
stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK)
was activated upon TSC1 knockdown (Fig 4F). Notably, the
increase in ROS production in P496-3 (Tet) cells as a result of
TSC1 knockdown could be normalized to control levels by mTORC1
inhibition through rapamycin treatment or by tetracycline-mediated
MYC repression (Fig 4E). Similarly, TSC2 knockdown resulted in
increased mitochondrial respiration and increased ROS levels in BL
cell lines (Fig EV4F). To examine whether elevated ROS levels are
responsible for the increased lethality of TSC1 knockdown cells, we
treated the cells with the antioxidant butylated hydroxyanisole
(BHA). BHA treatment restored survival of high MYC expressing
P493-6 cells after knockdown of TSC1 (Fig 4G), showing that ROS
production is responsible for the enhanced apoptosis.
Altogether, these data show that the combined activation of MYC
and mTORC1 leads to synergistic enhancement of mitochondrial
respiration, which increases ROS production to a level that induces
apoptosis. To prevent cell death by metabolic overloading, MYC
controls mTORC1 signaling in BL cancer cells through the upregula-
tion of TSC1.
MYC induces TSC1 involving transcription and suppression
of miR15a
Finally, we set out to investigate the mechanism of TSC1 regulation
by MYC. Steady-state TSC1 mRNA levels were increased in high
MYC (Tet) P493-6 cells compared to low MYC (+Tet) cells as
determined with qRT–PCR (Fig 1C) suggesting a regulation at the
level of either transcription or mRNA stability. However, pulse
labeling revealed only a moderately enhanced accumulation of
nascent TSC1 mRNA over 3 h in high (Tet) MYC cells (Fig 5A).
We used TFSEARCH software (Heinemeyer et al, 1998) to search
for potential MYC binding sites and found a single site in the
proximal TSC1-promoter (E-box: CACGTG, pos. 317/322). Using
TSC1-promoter-reporter constructs, we detected activation of the
TSC1-promoter upon coexpression of MYC in the presence of the
wild-type E-box although to a lower extend as of a control E-box
reporter. Mutation of the E-boxes resulted in loss of MYC-induced
activation (Fig 5B). These findings are in agreement with the
▸Figure 5. MYC controls TSC1 expression through transcriptional and miR-15a-mediated regulation.A Accumulation of EU-labeled (Click-It, Invitrogen) TSC1-mRNA over 3 h in high MYC (-Tet) versus low MYC (+Tet) P493-6 cells (mean  SD, n = 3 technical replicates).
B Drawing of the TSC1 promoter and luciferase reporter constructs with the predicted E-box (CACGTG, pos. 317/322) indicated. Relative luciferase units (RLU) of
co-transfection experiments using the indicated TSC1-promoter-reporters with MYC normalized to empty pcDNA3 expression vector in HeLa cells (mean  SD, n = 3).
Immunoblot shows MYC overexpression and a-tubulin as loading control.
C TSC1 mRNA turnover determined by pulse and chase (Click-It, Invitrogen) over 8 h in P493-6 cells, either treated with tetracycline to repress MYC or left untreated
(mean  SD, n = 3 technical replicates).
D miR-15a expression determined by qRT–PCR in P493-6 cells treated with tetracycline for 3 days (+Tet) to suppress MYC expression or in untreated (Tet) cells
(mean  SD, n = 3 technical replicates).
E Immunoblots showing expression levels of TSC1, S6K/P-S6K, and a-tubulin in P493-6 and HEK293T cells overexpressing miR-15a or a control miRNA. At the right, miR-
15a overexpression was determined by qRT–PCR in P493-6 and HEK293T cells (mean  SD, n = 3 technical replicates).
F Immunoblot showing TSC1 expression, S6K/P-S6K, and a-tubulin in MCF-7 cells transfected with LNA modified anti-sense miR-15a oligos or control LNAs. At the right,
successful miR-15a knockdown determined by qRT–PCR in MCF-7 cells is shown (mean  SD, n = 3 technical replicates).
G Relative luciferase units (RLU) derived from reporter constructs containing TSC1-30UTR wild-type sequences or with mutated miR-15a seed sequence binding site on
co-transfection with miR-15a in MCF-7 cells (mean  SD, n = 3 biological replicates). The drawing at the right shows the TSC1-30UTR with the position of the miR-
15a/16-1 seed sequence and used mutation indicated.
H Rate of oxygen consumption in P493-6 (Tet) cells ectopically expressing miR-15a or control miRNA vector, under basal conditions and in response to 10 lM DNP or
10 lM oligomycin where indicated (mean  SD, n = 8 biological replicates).
Data information: In all graphs *P < 0.05; **P < 0.01; ***P < 0.001, statistical relevance was determined by unpaired t-test (two-tailed).
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ENCODE database that records a MYC-associated DNA fragment of
intermediate signal strength covering the same sequence (http://ge
nome.ucsc.edu/ENCODE/). The rather modest transcriptional regu-
lation of TSC1 suggested that it might not be the sole mechanism
involved. Therefore, we performed a pulse-chase labeling experi-
ment, which revealed a strongly enhanced TSC1 mRNA turnover in
low MYC (+Tet) compared to high MYC (Tet) P493-6 cells
(Fig 5C), indicating that MYC function stabilizes the TSC1 mRNA.
Since MYC is a known regulator of microRNA (miRNA) expression
(Chang et al, 2008), we examined whether the observed increase in
mRNA turnover in response to MYC repression may be caused by
miRNA regulation, which generally results in deadenylation and
decay of target mRNAs. In search of potentially involved miRNAs,
we identified conserved binding sites for the MYC-suppressed
miRNAs miR-15a/16-1, -22, -23ab -26ab, -29abc, -30e-5p, and -195
in the 30untranslated region (30UTR) of the TSC1 mRNA by using
the TargetScan algorithm (www.targetscan.org). Importantly, those
miRNAs are direct MYC targets and were found to be among the
suppressed miRNAs in high MYC expressing BL patient samples
compared to B cells from hyperplastic tonsils or samples from
patients with MYC translocation negative non-Hodgkin lymphomas
(NHLs), including mantle cell lymphoma (MCL), follicular
lymphoma (FL), and chronic lymphocytic leukemia (CLL) (Robertus
et al, 2010; Table EV1). Overexpression of single miRNAs in
HEK293T cells revealed that miR-15a, miR-22, and miR-23a strongly
suppressed TSC1 and increased P-S6K with miR-15a having the
strongest effect on inducing phosphorylation of S6K (Fig EV5A).
MiR-15a and miR-16-1 have identical seed sequences and reside in
the DLEU2/miR-15a/16-1 cluster in the chromosomal region 13q14
whose deletion is commonly associated with the B-cell malignancy
chronic lymphocytic leukemia (B-CLL; Klein et al, 2010). It was
shown by others that MYC represses pri-microRNA 15a/16-1 tran-
scription in P493-6 cells through direct interaction with the pri-
microRNA promoter (Chang et al, 2008). Accordingly, we found
that induction of MYC reduced miR-15a levels in P493-6 cells
(Fig 5D). Overexpression of miR-15a in P493-6 and HEK293T cells
resulted in decreased TSC1 protein levels compared to the control
microRNA with concomitant induction of S6K phosphorylation in
both cell lines (Fig 5E). Moreover, knockdown of miR-15a in MCF-7
cells by transfection of LNA modified anti-sense miR-15a oligonu-
cleotides resulted in elevated TSC1 expression and reduced S6K
phosphorylation compared to cells that were transfected with
control LNAs (Fig 5F). Next, we examined whether miR-15a
suppresses TSC1 mRNA through direct interaction with the TSC1-
30UTR. Overexpression of miR-15a reduced the luciferase expression
from a TSC1-30UTR-driven luciferase reporter construct and muta-
tion of the miR-15a seed sequence relieved the miR-15a-mediated
repression (Fig 5G). Thus, the TSC1 mRNA is suppressed through
direct interaction with miR-15a. Although our experiments show
that miR-15a is sufficient for modulation of the TSC1-mTORC1 axis,
the other MYC-suppressed miRNAs that target TSC1 may further
solidify the regulation. Notably, oxygen consumption as well as
maximal respiratory capacity was also increased in P493-6 cells that
overexpress miR-15a (Fig 5H), revealing the crucial function of this
miRNA in the MYC-TSC1-mTORC1 regulatory pathway and in the
regulation of mitochondrial physiology. Furthermore, miR-15a over-
expression decreased cell viability in two BL cells (Fig EV5B). Taken
together, the results indicate that MYC augments TSC1 expression
by a feed-forward mechanism—one of the most common motifs in
transcriptional networks—combining the stimulation of TSC1 tran-
scription with the alleviation of miR-15a function and thereby
increasing TSC1 mRNA stability.
Discussion
The proto-oncogene MYC is often deregulated in human cancers yet
therapeutic strategies to directly target MYC are currently not avail-
able. Identifying synthetic lethal interactions with oncogenic func-
tions of MYC may lead to new therapeutic strategies. In this study,
we present a connection between MYC and mTORC1 in Burkitt’s
lymphoma that may provide the foundation for novel therapeutic
opportunities. MYC induces the expression of the mTORC1 inhibitor
TSC1 through stimulation of TSC1 transcription and downregulation
of miR-15a that targets the TSC1-mRNA. Other identified MYC-
repressed and TSC1-targeting microRNAs that were not further inves-
tigated here may reinforce this regulation. The upregulation of TSC1
by MYC results in the attenuation of mTORC1 signaling in order to
safeguard mitochondrial homeostasis and thereby preventing the
accumulation of toxic ROS levels. In addition, knockdown of either
TSC1 or TSC2 results in an upregulation mTORC1 signalling, accom-
panied by enhanced mitochondrial respiration, elevated ROS levels,
and reduced cell viability, showing that the effects are not specific for
TSC1 but related to TSC1/2 complex function. Since TSC1/2 is gener-
ally considered to function as a tumor suppressor (Mieulet & Lamb,
2010) and elevated mTORC1 signaling has been detected in a large
proportion of human cancers including B-cell malignancies (Dazert &
Hall, 2011), our finding was surprising. However, we detected
elevated TSC1/2 expression in tumors of two independent cohorts of
BL patients and in several BL-derived cell lines. Furthermore, our
data show that TSC1/2 controls mTORC1 in BL and is crucial for
survival in MYC overexpressing cells. Altogether, this argues against
a role for TSC1/2 in tumor suppression in human BL, but rather for a
role in tumor maintenance. We propose a model for BL in which a
window of mTORC1 activity that supports cell survival is controlled
by MYC through maintenance of TSC expression (Fig 6). In sponta-
neously immortalized rat fibroblast (Rat1A cell lines), Myc was
shown to repress TSC2 transcription resulting in increased S6K activ-
ity and soft agar colony formation (Ravitz et al, 2007), which seems
to be at odds with our findings. Notwithstanding, our data clearly
reveal a positive correlation between high MYC and high TSC1/2
levels in BL cell lines as well as in patient material (Figs 1A and 2),
and the positive transcriptional and post-transcriptional regulation of
TSC1 transcript by MYC (Figs 1C and D, and 5A–C). Possibly, these
apparently opposing results are caused by different wiring of TSC2
regulation in fibroblasts and BL cells. In support of our finding is a
study in the fly D. melanogaster where TSC was identified as an
essential regulator of intestinal stem cells in the Drosophila midgut,
using an RNAi-based genetic screen. Loss of TSC results in excessive
cell growth and halted cell division, which is rescued by reducing
Myc levels or inhibition of TORC1 by treatment with rapamycin
(Amcheslavsky et al, 2011). The latter study and the data presented
here show that at least in certain context high MYC levels are incom-
patible with high mTORC1 activation.
Activation of mTORC1 in cancer has been shown in numerous
studies (Zoncu et al, 2011). mTORC1 and MYC have overlapping
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functions, including stimulating effects on cell growth and prolifera-
tion, ribosome biogenesis, and protein synthesis. In addition,
mTORC1 induces oxidative phosphorylation by facilitating YY1/
PGC1a complex formation (Cunningham et al, 2007) and supports
aerobic glycolysis (Duvel et al, 2010). In the El-Myc mouse model,
mTORC1 activation was shown to accelerate lymphomagenesis by
inhibiting Myc-induced apoptosis through translational upregulation
of the anti-apoptotic protein myeloid cell leukemia 1 (Mcl1; Mills
et al, 2008), suggesting a collaboration of Myc and mTORC1 in
tumor initiation. On the contrary, MYC amplification was shown to
confer resistance to mTORC1 inhibition through transcriptional acti-
vation of the eukaryotic translation initiation factor 4E (eIF4E),
suggesting that mTORC1 function is not critical in the context of high
MYC expression (Ilic et al, 2011). Correspondingly, in a chemical
screen study elevated MYC levels correlated with enhanced resis-
tance to PI3K/mTORC1 inhibition (Muellner et al, 2011). In line with
our study, others have shown that deregulation of MYC may result
in energy (ATP) depletion and suppression of mTORC1 through the
activation of NUAK1/ARK5-AMPK, which is required for metabolic
homeostasis and cell survival (Liu et al, 2012). However, this regula-
tion may not be relevant for BL and other leukemia, since the CCLE
data (http://www.broadinstitute.org/ccle) reveal that NUAK1/ARK5
mRNA expression is very low in most leukemia and lymphoma-
derived cell lines, compared to cell lines derived from solid tumors
(Fig EV5C). Altogether, multiple studies suggest that MYC-driven
oncogenesis does not obligatory require mTORC1 activation and that
time- and dose-dependent variation in mTORC1 signaling may be
required for different stages of tumor development.
Our study for the first time reveals a tumor maintenance function
for TSC1/2 and thereby questions the general role of the TSC1/2
complex as a tumor suppressor. Although our results point to canoni-
cal mTORC1 inhibition as being responsible for the tumor mainte-
nance activity, we cannot rule out the involvement of other TSC1/2
functions. So far, we do not know whether the requirement of TSC1/2
for cancer cell survival is restricted to BL or whether it might be a char-
acteristic also for other MYC-driven cancers. Nonetheless, in specific
cancer (sub-)types, the inhibition of TSC1/2 function or the activation
of mTORC1 may be considered for a novel therapeutic strategy.
Material and Methods
Cell culture and plasmids
P493-6, Raji, BL2, Ramos, DG75, CA46, ST486, Jiyoye, EW36,
AG876, KMH2, L428, L450, L1236, and MCF-7 cells were main-
tained in RPMI 1640. HEK293T, U2OS-MYC-ER cells (Liu et al,
2012), wt MEFs, and TSC1-deficient MEFs (Hsieh et al, 2012) were
maintained in DMEM. All media were supplemented with 10% FCS
(Tet-free FCS from Clontech was used for P493-6 cells) or 15%
(EW36, AG876, KMH2, L428, L450, and L1236), non-essential
amino acids, and penicillin/streptomycin. For repression of MYC in
P493-6 cells, 0.1 lg/ml tetracycline was added to the culture
medium, and for activation of MYC in U2OS-MYC-ER cells, the
culture medium was supplemented with 100 lM hydroxytamoxifen
(4-OHT) for 4 days. Rapamycin was added in a concentration range
from 30 pM to 100 nM for different time periods. For antioxidant
treatment, cells were grown for 3 days in the presence of 1 lM
butylated hydroxyanisole (BHA, Sigma-Aldrich).
Transfection and transduction
HEK293T cells were seeded to a density of 2 × 106 cells in 10-cm
culture dishes. 24 h later, transfection was carried out using the
calcium phosphate method. pcDNA-6.2-GW/EmGFP-miRNA (Invit-
rogen)-based microRNA expression vectors were transfected in
P493-6 cells using the Amaxa Nucleofector (Lonza) following the
manufacturer’s instructions, and stable microRNA expressing cell
lines were obtained by selecting on blasticidin. Locked nucleic acids
(LNA) anti-miR-15a and control LNAs (Exiqon) were transfected
using HiPerfect (Qiagen) in 6-well plates following the manufac-
turer’s instructions. Cells were harvested after 72 h. Transfection of
P493-6 cells with self-delivery Accell siRNAs (Dharmacon) was
performed according to the provider’s instructions in 96-well plates.
MicroRNA expression vectors were generated using the Block-it
system (Invitrogen) using the pcDNA-6.2-GW/EmGFP-miR- vector.
Cells were infected following a standard protocol with pLKO.1
lentiviral constructs containing shRNAs against human TSC1: sh-a
50-CCG GGC ACT CTT TCA TCG CCT TTA TCT CGA GAT AAA GGC
GAT GAA AGA GTG CTT TTT G-30; sh-b 50-CCG GGC CAA GAA
AGA CCA CCT TCT TCT CGA GAA GAA GGT GGT CTT TCT TGG
CTT TTT G-30, TSC2: 50-CCG GGC TCA TCA ACA GGC AGT TCT
ACT CGA GTA GAA CTG CCT GTT GAT GAG CTT TTT G-30 and
MYC: 50-CCG GCC TGA GAC AGA TCA GCA ACA ACT CGA GTT
GTT GCT GAT CTG TCT CAG GTT TTT G-30 or non-target shRNA
control (Sigma-Aldrich). Stable shRNA expressing cells were
obtained by selection on puromycin.
MicroRNA expression plasmids
MicroRNA expression vectors were generated using the Block-it
system (Invitrogen). Briefly, oligos were phosphorylated, annealed,
Figure 6. Model of the MYC-miR-15a-TSC1 axis controlling mTORC1
activity.
Hyperactivation of mTORC1 through loss of TSC1 function results in metabolic
stress, ROS production, and apoptosis. Under this condition, low dose of
rapamycin restores mTORC1 levels that are compatible with cell viability.
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and ligated with the pcDNA-6.2-GW/EmGFP-miR- vector following
the manufacturer’s instructions. The following oligos were used for
ligation: miR-15a 50-TGC TGT AGC AGC ACA TAA TGG TTT GTG
GTT TTG GCC-30 (top strand) and 50-ACT GAC TGA CCA CAA ACC
TAT GTG CTG CTA-30 (bottom strand), miR-22 50-TGC TGA AGC
TGC CAG TTG AAG AAC TGT GTT TTG GCC ACT GAC TGA CAC
AGT TCT AAC TGG CAG CTT-30 (top strand) and 50-CCT GAA GCT
GCC AGT TAG AAC TGT GTC AGT CAG TGG CCA AAA CAC AGT
TCT TCA ACT GGC AGC TTC-30 (bottom strand), miR-23a 50-TGC
TGA TCA CAT TGC CAG GGA TTT CCG TTT TGG CCA CTG ACT
GAC GGA AAT CCG GCA ATG TGA T-30 (top strand) and 50-CCT
GAT CAC ATT GCC GGA TTT CCG TCA GTC AGT GGC CAA AAC
GGA AAT CCC TGG CAA TGT GAT C-30 (bottom strand), miR-26a
50-TGC TGT TCA AGT AAT CCA GGA TAG GCT GTT TTG GCC ACT
GAC TGA CAG CCT ATC GGA TTA CTT GAA-30 (top strand) and 50-
CCT GTT CAA GTA ATC CGA TAG GCT GTC AGT CAG TGG CCA
AAA CAG CCT ATC CTG GAT TAC TTG AAC-30 (bottom strand),
miR-29a 50-TGC TGT AGC ACC ATC TGA AAT CGG TTA GTT TTG
GCC ACT GAC TGA CTA ACC GAT CAG ATG GTG CTA-30 (top
strand) and 50-CCT GTA GCA CCA TCT GAT CGG TTA GTC AGT
CAG TGG CCA AAA CTA ACC GAT TTC AGA TGG TGC TAC-30
(bottom strand), miR-30e 50-TGC TGT GTA AAC ATC CTT GAC
TGG AAG GTT TTG GCC ACT GAC TGA CCT TCC AGT AGG ATG
TTT ACA-30 (top strand) and 50-CCT GTG TAA ACA TCC TAC TGG
AAG GTC AGT CAG TGG CCA AAA CCT TCC AGT CAA GGA TGT
TTA CAC-30 (bottom strand), and a non-targeting miRNA was used
as a control (Invitrogen).
Immunoblotting
Immunoblotting was performed as described earlier (Zidek et al,
2015) with the following antibodies: from Cell Signaling Technology,
anti-TSC1 (#4906), anti-TSC2 (#4308); anti-pS6K (Thr389) (#9206)
and (Thr389) (#9234), anti-S6K (#9202), anti-pS6 (Ser235/236)
(#2211), anti-S6 (#2317), anti-pSAPK/JNK (Thr183/Tyr185) (#9251);
anti-p-4E-BP1 (T37/46) (#9459); anti-p-AKT (Ser473) (#4060); anti-
AKT (#9272); anti-MYC (#5605); from Sigma-Aldrich, anti-b-actin
(A3853); from Santa Cruz Biotechnology, anti-a-tubulin (sc-8035),
anti-TSC2 (sc-893), anti-MYC (sc-40), anti-SAPK/JNK (sc-571); and
from MP Biomedicals, anti-b-actin (#69100). Bands were visualized
by chemoluminescence (Western Lightning Plus-ECL, Perkin Elmer).
qRT–PCR
RNA was isolated using the RNAeasy kit (Qiagen), and cDNA
synthesis was done using the first strand cDNA kit (ROCHE). qRT–
PCR was performed on a LC480 Light Cycler (Roche) using SYBR
Green (Roche) and the following primers: TSC1 50-CAA ACT CCA
GGC AAG AGG AC-30 (forward) and 50-CCA ATT CAA ACA CCT
GGG TTA-30 (reverse), TSC2 50-TGC AAG CCG TCT TCC ACA T-30
(forward) and 50-ATG GAC ACA AAG TCG TTG C-30, b-actin 50-AGA
GGG AAA TCG TGC GTG AC-30 (forward) and 50-CAA TAG TGA
TGA CCT GGC CGT-30 (reverse), ATP5G1 50-AGG GCT AAA GCT
GGG AGA CTG AA-30 (forward) and 50-GTC TGG CCA CCT GGA
GTG GGA-30 (reverse), CYCS 50-AGG GAC AGA ATT TAA ATA TGG
GTG A-30 (forward) and 50-AGA TTT GGC CCA GTC TTG TG-30 (re-
verse), HPRT (for normalization) 50-TGA CAC TGG CAA AAC AAT
GCA-30 (forward) and 50-GGT CCT TTT CAC CAG CAA GCT-30
(reverse). For microRNA qRT–PCR, RNA was isolated using the
miRNeasy kit (Qiagen), and primers obtained from the miScript
System (Qiagen) were used for expression analysis with a primer for
U6 RNA used for normalization. Primers for the analysis of mito-
chondrial DNA to genomic DNA ratio: genomic glucagon-intron 50-
TGA CAA AGA CGG ACT TGA CG-30 (forward) and 50-CCC TGT
GTC ACA AGC AGA TG-30 (reverse); mitochondrial COX2 50-TTC
ATG ATC ACG CCC TCA TA-30 (forward) and 50-TAA AGG ATG
CGT AGG GAT GG-30 (reverse).
mRNA labeling experiments
TSC1 nascent transcription or mRNA stability was determined using
the Click-It Nascent RNA Capture Kit (Invitrogen) according to the
protocol of the manufacturer. P493-6 cells were grown for 3 days in
the absence or presence of tetracycline. Cells were seeded in a
concentration of 1 × 106 cells/ml growth medium (RPMI), and
mRNA was labeled with 5-ethynyl uridine (EU) in a final concentra-
tion of 200 lM in the absence or presence of tetracycline. Cells were
harvested after 3-h labeling for analysis of initial transcription rates.
For pulse chase, cells were labeled o.n., washed twice with PBS,
and chased for different time points with normal growth medium in
the absence or presence of tetracycline. Non-labeled cells were used
as control (for each time point, 1.5 × 107 cells were used). Total
RNA was prepared using the RNeasy kit from Qiagen, and 2 lg RNA
was biotinylated using 0.5 mM biotin azide. After RNA precipita-
tion, the biotinylated RNA was isolated using Streptavidin T1
magnetic beads and used for cDNA synthesis using the SuperScript
Reverse Transcriptase (Roche). The amount of biotinylated hTSC1
mRNA was determined by qRT–PCR on a LC480 Light Cycler
(Roche) and normalized to b-actin mRNA levels.
Luciferase assay
Luciferase constructs were obtained by cloning TSC1-30UTR sequence
containing miR-15a binding site into pGL3 Vector (Promega). Briefly,
30UTR sequence was PCR amplified using the following primers: 50-
ATG CTC TAG ATC TGC TGC ACC TTC ACT CTC-30 (forward) and
50-ATG CTC TAG AGC AAA ATC TGT TCC TCC GTA A-30 (reverse),
XbaI digested and ligated into the XbaI restriction site of the pGL3-
promoter vector. For site-directed mutagenesis of the miR-15a bind-
ing site by PCR, the following primers were used: 50-GAC AGG AGG
TAT GGC GAT CCT CTG TGT AGC A-30 (forward) and 50-TGC TAC
ACA GAG GAT CGC CAT ACC CTC CTG TC-30 (reverse). For the luci-
ferase assay, 2 × 104 MCF-7 cells per well were seeded into 96-well
plates. After 24 h, cells were co-transfected with TSC1-30UTR-pGL3
luciferase reporter, Renilla reporter, and either miR-15a or control
pcDNA-6.2-GW/EmGFP-miRNA expression vectors. After additional
24 h, luciferase activity was measured using the Stop and Glow kit
(Promega) following the manufacturer’s protocol with a Mithras LB
940 (Berthold technologies).
For generating the TSC1-promoter luciferase reporters, TSC1
promoter fragments were amplified by PCR from genomic DNA
using following forward primers: E1wt 50-GCG GGT ACC GGG CGC
TCC AAC CAC ACC CAG-30, in combination with the reverse primer
50-GCG CTC GAG CTT GGA CGT ACA GCA CCT CCC-30. The muta-
tion of E-box (E1mut) was performed by PCR using the forward
primer for E1wt and the reverse primer as outer primers, and the
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primers: 50-CCG CCC GCC AGT CAC CCG ACC GCC CGC CCC-30 and
50-GGG GCG GGC GGT CGG GTG ACT GGC GGG CGG-30 carrying
the mutation. PRC fragments were digested with KpnI and XhoI and
cloned into the pGL3-Basic Firefly luciferase vector (Promega). The
pTK-Ap2/E (renamed in E-boxRep) and pTK-AP2/mut4 (renamed in
E-boxRepMut) E-box luciferase reporter constructs were obtained
from Martin Eilers (Gaubatz et al, 1995). 20 h before transfection,
HeLa cells were seeded in a 96-well plate (5,000 cells per well).
Transfection was performed in triplicates using 100 ng pGL4 Renilla
vector, 300 ng Firefly reporter, and either 600 ng pcDNA3, 600 ng
pCMV-Myc, and 3 ll Fugene (Promega) according to the protocol of
the manufacturer. 5 h after transfection, medium was exchanged,
and luciferase activity was analyzed 48 h after transfection by using
the Stop and Glow kit (Promega) with a Mithras LB 940 (Berthold
Technologies).
Measurement of oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR)
To measure the rate change of dissolved oxygen (oxygen consump-
tion rate) in the culture medium, a Seahorse XF96 was used. To
calculate the ratio of oxygen consumption over lactate production,
the pH change in the medium (acidification rate as indirect method
for lactate production) was measured simultaneously. Between
4 × 104 and 8 × 104 cells were seeded in unbuffered DMEM in poly-
lysine treated XF96 plates 1 h prior to the assay, and the measure-
ment was made over 2 min. Rapamycin (20 nM) treatment was
done for 12 h prior to the measurement. Concentrations of the
injected drugs were as follows: oligomycin (10 lM), 2,4-dinitro-
phenol (DNP) (10 lM), FCCP (600 nM), all from Sigma-Aldrich.
Apoptosis assay and ROS measurement
To determine apoptosis, the AnnexinV/7AAD Apoptosis detection
kit from BD Biosciences was used. Cells were treated according to
the manufacturer’s protocol and analyzed by FACS using a BD
FACSCanto II. For cell multiplication, equal number of viable cells
(Trypan blue exclusion) were seeded and assayed for viability
3 days after seeding, using a cell viability assay from Promega (Cell-
Titer Glo). For ROS measurements, cells were incubated with 10 lM
DCF-DA (Sigma-Aldrich) or 5 lM CellRox (Invitrogen) for 30 min
under normal culture conditions, washed and subjected to FACS
analysis using a BD FACSCanto II.
Tumor xenotransplant mouse studies
4.5 × 106 Ramos cells, expressing either a scrambled shRNA or a
shRNA against TSC1 (titer 1 × 108, MISSION shRNAs, Sigma), were
inoculated into immunodeficient NOD/SCID mice (n = 8/group)
subcutaneously, and tumor growth was monitored over time.
Tumor volume was calculated in all experiments according to
V = (length × width2)/2, and animals were sacrificed when tumor
size exceeded 2 cm3. Mice experiments were performed by EPO
GmBH (Berlin, Germany) according to the German Animal Protec-
tion Law with permission of the responsible authorities. Statistical
significance was determined by unpaired t-test (two-tailed). The
experiment was not randomized. The investigators were not blinded
to allocation during the experiment.
Tissue samples
Individual diagnoses were reviewed by an experienced
hematopathologist for consistent morphology and immunopheno-
type according to the 2008 WHO classification (Swerdlow et al,
2008). Pediatric BL presented with abdominal mass and was
CD10+, BCL2, and MYC/8q24 breakpoint positive. All protocols
for obtaining human tissue samples were performed in accordance
to the guidelines from the Institutional Review Board or Medical
Ethical Committee of the University Medical Center Groningen and
University Hospital Jena.
Histological analysis
Lymph node and Burkitt’s lymphoma (BL) tissue sections were
deparaffinized; heat-mediated antigen retrieval was done in citrate
buffer for 15 min at the sub-boiling point. Sections were cooled
down to room temperature, washed three times with PBS, and were
then blocked with 2% BSA in PBS for 1 h at room temperature.
Primary antibody was incubated in 1% BSA, in a humidified cham-
ber o.n. at 4°C with the following dilutions: TSC1 (Abcam, ab 40872)
1:75, CD20 (Abcam, ab 9475) 1:20, MYC (Abcam, ab 39688) 1:50,
P-S6 (Ser235/236) (Cell Signaling Technology, #4857) 1:75. Sections
were washed with PBS and incubated with the fluorescence-conju-
gated secondary antibody (Alexa Fluor 488 goat anti-rabbit or Alexa
Fluor 568 goat anti-mouse, Invitrogen) in 1% BSA for 2 h at room
temperature. After washing with PBS, sections were sealed with
coverslips in diamine phenylindole (DAPI) containing mounting
medium (Fluoroshield, ImmunoBioScience Corp.). Microscopic anal-
ysis was performed with the Zeiss AxioImager Z1 microscope. For
the quantification of TSC1 and MYC staining in CD20-positive B
cells, images (200× magnified) of seven follicles of the superficial
cortex of three control lymph nodes each (21 images) were
compared with seven images taken from eight BL samples derived
from different sites, lymph node (4×), cerebellum (1×), bone marrow
(1×), oropharynx (1×), nasopharynx (1×). Analysis was performed
using CellProfiler (Carpenter et al, 2006). Nuclei were visualized by
the DAPI staining, and the cell outline was identified from the TSC1
staining. The TSC1-positive cytoplasm was identified by subtracting
the nuclear area from the cell outline, and TSC1 fluorescence intensi-
ties were measured in the cytoplasm of an average of 1,500 cells per
image. Statistical significance of mean fluorescence intensities was
tested with the t-test (unpaired, two-tailed) using R (R Development
Core Team (2008). “R: A Language and Environment for Statistical
Computing”. from http://www.R-project.org).
Expanded View for this article is available online.
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